Stages II-III Breast Cancer

Kisqali® Receives FDA Approval as First Line Treatment for HR+/HER2- Metastatic Breast Cancer (03-16-2017)

The US Food and Drug Administration (FDA) has approved the investigational drug Kisqali® (ribociclib, LEE011) for first line treatment of hormone receptor + HER 2- metastatic breast cancer because when combined with Femera (letrozole) the combination... Continue Reading

Neratinib Improves Cancer-Free Survival in Early Breast Cancer (07-27-2016)

The targeted agent neratinib (PB272), which is still in clinical trials, demonstrated an improvement in cancer-free survival when used after Herceptin® (trastuzumab) in early-stage, HER2-positive breast cancer. Approximately 20-30% of breast cancer is... Continue Reading

Some Premenopausal Women Benefit from Exemestane Compared to Tamoxifen (04-28-2016)

Among premenopausal women with hormone-positive, early breast cancer who are considered to have a high risk of a cancer recurrence, the use of Aromasin® (exemestane) versus tamoxifen improves cancer-free survival at 5 years. These results were recently... Continue Reading

Dose-Dense Chemotherapy for Premenopausal Breast Cancer Improves Survival (03-28-2016)

Premenopausal women who have been diagnosed with breast cancer have improved survival if their chemotherapy doses are delivered every two weeks, compared to every three weeks. These results were recently presented at the 2016 European Breast Cancer Conference... Continue Reading

ASCO Publishes Breast Cancer Survivorship Guidelines (01-25-2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal... Continue Reading

Conjugate Drug Extends Survival in Patients with Advanced HER2-Positive Breast Cancer (01-3-2016)

Patients with metastatic, HER2-positive breast cancer received a combination antibody/chemotherapy drug in a phase 3 clinical trial survived longer, on average, than patients receiving other treatments. Researchers from Dana-Farber Cancer Institute reported... Continue Reading

A Vegan or Vegetarian Diet May Help Improve Treatment of Triple-Negative Breast Cancer (09-16-2015)

Early research suggests that a vegan or vegetarian diet low in the amino acid methionine may help improve treatment of triple-negative breast cancers. These findings were reported in the journal Clinical Cancer Research. The majority of breast cancers... Continue Reading

Biomarker May Help Improve Treatment of Triple-Negative Breast Cancer (09-8-2015)

Researchers have found a biomarker that appears active in the growth and spread of triple-negative breast cancer. Known as interleukin-13 receptor alpha 2 (IL13Ralpha2), the biomarker may help doctors identify patients at high risk of disease spread and... Continue Reading

Women with Early Breast Cancer Have Fewer Side Effects with Shorter Courses of Radiation (09-1-2015)

Women with early breast cancer have fewer side effects when they’re treated with shorter courses of radiation at higher doses than with conventional radiation to the whole breast. These findings were reported in JAMA Oncology.[1] Treatment with shorter... Continue Reading

Role of Tumor Size and Estrogen-Receptor Status in Decline in Breast Cancer Deaths (08-4-2015)

In light of a general decline in breast cancer death since the late 1980s, research has now turned to how type and stage of disease affect survival among different women. These findings, which considered tumor size and estrogen-receptor (ER) status,... Continue Reading

Next Page »